Quick refresher: Wegovy is approved by the Food and Drug Administration for chronic weight management in adults with either obesity (body mass index, or BMI, of 30+) or overweight (BMI of 27+) with at least one weight-related medical condition, such as type 2 diabetes, high blood pressure, or high cholesterol
At the time of writing, retatrutide is not yet widely approved for clinical use in the UK
F., Vergari, E., Zhang, Q
Table: Key Deadlines and Conditions for Compounding Semaglutide EntityDeadlineConditionsState-licensed pharmacy (503A)April 22, 2025, or court decision, whichever is laterNo action for violations depending on shortage list inclusionOutsourcing facilities (503B)May 22, 2025, or court decision, whichever is laterNo action for violations depending on shortage list inclusion Note: The court decision refers to the preliminary injunction motion in OFA v
Small, lower-fat meals with moderate viscosity and adequate protein and fibre content may help reduce GI discomfort and improve treatment adherence [60]
